Hepion Pharmaceuticals: director Fisher Danina bought 400,000 shares

What happened Fisher Danina, a director of Hepion Pharmaceuticals, purchased 200,000 shares at $0.05 per share for $10,000 and acquired 200,000 derivative shares at $0.00 on Sep 29, 2026, according to the Form 4.

Key details

• Transaction date: Sep 29, 2026.
• Transactions reported: 200,000 common shares purchased at $0.05 per share (total $10,000); 200,000 derivative shares acquired at $0.00 (total $0).
• Transaction codes: P (purchase) for both reported transactions.
• Filing date: Oct 2, 2026.
• Shares owned after the transaction: not reported in the filing.
• Footnotes: filing classifies the second 200,000 shares as derivative acquisition; no 10b5-1 plan, tax withholding, or late-filing flag reported in the data provided.

Why it may matter The filing shows a market purchase and a separate acquisition of derivative shares. The filing does not show why the insider traded or why the company acted.